Prot# B9E-US-X446: A Phase I/II Trial of Combination Bortezomib (VELCADE®) and Gemcitabine Therapy for Patients with Relapsed or Refractory Aggressive B- and T -Cell Non-Hodgkin's Lymphoma (NU Prot# NU 04H4)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/12/0510/31/17

Funding

  • Eli Lilly and Company (B9E-US-X446 / NU 04H4)